PET imaging of hypoxia

Quarterly Journal of Nuclear Medicine

Volumn 45, Issue 2, 2001, Pages 183-188

  Lewis, J S ^a   Welch, M J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell hypoxia; Neoplasms, radionuclide imaging; Radiopharmaceuticals; Tomography, emission computed

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANTINEOPLASTIC AGENT; BMS 194796; COPPER DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE); IODINE 123; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; OXYGEN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; UPENAZIME TC 99M;

CANCER; CANCER RADIOTHERAPY; CELL HYPOXIA; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG TARGETING; HUMAN; MALIGNANT TRANSFORMATION; NON INVASIVE MEASUREMENT; NUCLEAR MEDICINE; ONCOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY;

CELL HYPOXIA; HUMANS; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034938846     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (68)

1. The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture
2. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
3. The action of radium on cancer cells I. II. Some factors determining the susceptibility of cancer cells to radium
4. Responses of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions
5. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma
6. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
7. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
8. Oxygen in human tumors: Correlations between methods of measurement and response to therapy
9. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
10. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
11. Measurement of tumor oxygenation: A comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor
12. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats
13. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the 'Comet' assay
14. Detection of hypoxic cells in a murine tumor with the use of the comet assay
15. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3,-pentafluoropropyl)acetamide]: Analysis of drugs adducts by fluorescent antibodies versus bound radioactivity
16. Determination of microvascular oxyhemoglobin saturations using cryospectrophotometry
17. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow
18. Functional magnetic resonance (fMR) imaging of a rat brain tumor model: Implications for evaluation of tumor microvasculature and therapeutic response
19. 2 tension measurements in a murine fibrosarcoma
20. 31P magnetic resonance spectroscopy is sensitive to tumor hypoxia: Perfusion and oxygenation of rat 9L gliosarcoma after treatment with BCNU
21. 19F magnetic resonance method for measuring oxygen deficiency in tumors
22. 19F magnetic resonance spectroscopy and immunohistochemistry
23. Nitroimidazoles and imaging hypoxia
24. 123I-iodoazomycin arabinoside: Preliminary report of a clinical study
25. Imaging tumor hypoxia and tumor perfusion
26. Technetium-99m-nitromidazole uptake in a swine model of demand ischemia
27. "Hot spot" detection of ischemic myocardium in vivo by gamma camera imaging
28. Comparison of two novel technetium agents for imaging ischemic myocardium
29. Kinetic analysis of technetium-99m-labeled nitromidazole (BMS181321) as a tracer of myocardial hypoxia
30. 99mTc-nitroimidazole complex BMS-194796
31. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia
32. Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG
33. Technetium 99m-HL-91: A potential new marker of myocardial viability assessed by nuclear imaging early after reperfusion
34. HL-91-technetium-99m: A new marker of viability in ischemic myocardium
35. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro
36. Radio-labeled fluoromisonidazole as an imaging agent for tumor hypoxia
37. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole
38. 18F]fluoromisonidazole: A pretherapy study of 37 patients
39. 4-methylthiosemicarbazone): Effect of changes in tissue oxygenation
40. 64Cu-ATSM) in vivo and in vitro in a hypoxic tumor model
41. Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro
42. Redoxactive complexes for imaging hypoxic tissues: Structure-activity relationships in copper(II)bis(thiosemicarbazone) complexes
43. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential
44. 64Cu-ATSM a hypoxia imaging agent and C-11-acetate in an acute myocardial infarction model: Ex vivo imaging in rats
45. Structure-function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells
46. Evaluation of cardiac ischemia by NADH fluorescence photography
47. Quantification of Cu-ATSM kinetics by compartmental modeling in normal, ischemic and necrotic myocardium
48. 4-methylthiosemicarbazone) (Cu-ATSM), a hypoxia imaging agent, in canine models of ischemia
49. 64Cu using a biomedical cyclotron
50. High purity production and potential applications of copper-60 and copper-61
51. A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals
52. 4-methylthiosemicarbazonato)copper(II): Synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion
53. The zinc-62/copper-62 generator: A convenient source of copper-62 for radiopharmaceuticals
54. 62Cu-PTSM
55. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy
56. Evaluation of tumor hypoxia with Cu-60-ATSM and PET
57. 60Cu]ATSM in human neoplasms
58. 4-methyl-thiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer
59. 4-methylthiosemicarbazone): An agent for radiotherapy
60. Chemical modifiers of cancer treatment
61. Tirapazamine: Laboratory data relevant to clinical activity
62. Bioreductive therapies: An overview of drugs and their mechanisms of action
63. Role of radionuclide imaging in trials of anti-angiogenic therapy
64. Influence of an anti-angiogenic treatment of 9L gliosarcoma: Oxygenation and response to cytotoxic therapy
65. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only
66. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis